 Senti Biosciences Inc, the synthetic biology play helmed by MIT whiz Tim Lu, will be merging with Farokhzads Dynamics Special Purpose Corp NASDAQ: DYNS in a deal set to deliver 296 million in gross proceeds. Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. 